Investor Relations

Press Releases

Advaxis to Present at the LD Micro Conference

Read More

Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program

Read More

Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer

Read More

Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer

Read More

Advaxis to Present Survival Data of Lm-LLO Cancer Immunotherapies in Recurrent Cervical Cancer and Canine Osteosarcoma at the Society for Immunotherapy of Cancer 29th Annual Meeting

Read More

Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study

Read More

Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer

Read More

Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

Read More

Advaxis's Lm-LLO Immunotherapy Data to be Presented in Three Posters at the Society for Immunotherapy of Cancer 29th Annual Meeting

Read More

Advaxis Appoints World Renowned Oncologist and Research Scientist, Dr. Samir N. Khleif, to Its Board of Directors

Read More